PT  - JOURNAL ARTICLE
AU  - D. Lynn Kirkpatrick
AU  - Jeffrey Millard
TI  - Evaluation of nafamostat mesylate safety and inhibition of SARS-CoV-2 replication using a 3-dimensional human airway epithelia model
AID  - 10.1101/2020.09.16.300483
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.09.16.300483
4099  - http://biorxiv.org/content/early/2020/09/16/2020.09.16.300483.short
4100  - http://biorxiv.org/content/early/2020/09/16/2020.09.16.300483.full
AB  - In the current COVID-19 pandemic context, Ensysce and its subsidiary Covistat have been working to repurpose nafamostat mesylate as an effective oral and inhalation treatment against SARS-CoV-2 infection. Prior reports used cell lines to demonstrate the antiviral potential of nafamostat against coronaviral infections and determined its mechanism of action through inhibition of transmembrane protease serine 2 (TMPRSS2). We selected a biologically relevant pre-clinical experimental model of SARS-CoV-2 lung infection using a 3D human reconstituted airway epithelial model of nasal origin to characterize the effects of nafamostat on tissue-level cellular ultrastructure and viral infection kinetics. Our results confirm the not only the relevance of this model for the preclinical evaluation of safety and efficacy of antiviral candidates, but also the highly potent nature of nafamostat SARS-CoV-2 antiviral activity. The studies described herein provided evidence demonstrating the therapeutic potential of nafamostat against COVID-19, as well as its safety upon exposure to lung airway cellular.One Sentence Summary Using a human airway model, study demonstrates the powerful inhibitory effect of nafamostat on SARS-CoV-2 genome copy detection when applied apically.Competing Interest StatementL Kirkpatrick and J Millard are employees of Ensysce Biosciences Inc.